Axio BioPharma

Axio BioPharma provides AI-enhanced contract development and manufacturing services focused on mammalian-expressed proteins—especially monoclonal antibodies. Their proprietary machine learning-driven platform accelerates process development by simulating purification workflows, optimizing conditions, and reducing trial-and-error experimentation. The company currently offers research-grade production from small-scale discovery batches up to preclinical volumes, with plans to expand into full GMP clinical manufacturing by early 2028. No direct clinical results are reported as they serve as a CDMO rather than developing their own therapeutics.